Kaye Edward M. MD

Director Edward M. Kaye sold 28,064 shares (28.1K) of CYTK for $1,872,430.08 ($1.9M); -73.8% of pre-transaction holdings; stock -6.8% from 52-week high.

Director Kaye divested 28,064 shares at $66.72, reducing his stake from 38,041 to 9,977 shares—a substantial 73.8% reduction in his holdings. The sale occurred near the 52-week high of $68.15, approximately 6.8% below that peak, within a period when the stock has appreciated 27.0% over 90 days. The company reported a net loss of $306,178,000 in its most recent full fiscal year while delivering 145.3% annual revenue growth—a pattern consistent with early-stage growth companies burning cash to scale. Kaye's cross-ticker track record shows a 40.00% well-timed rate on six prior sells, though this specific transaction's timing against CYTK's future performance remains to be observed.

Director Kaye Edward M. MD sold 42,461 shares of STOK at $25.09 on 2025-10-03, reducing holdings 46.4%; stock now at $27.31 (+0.0% from 52-week high, +127.2% in 90 days).

Kaye sold 42,461 shares for a total value of $1,065,206.37, reducing his position from 91,585 shares to 49,124 shares. This represents a substantial reduction of his stake at a price $2.22 below the current $27.31, amid a dramatic 127.2% surge in the stock price over the prior 90 days and 32.1% gain in the prior 30 days. The sale follows a pattern of four prior sales at STOK within the last month (on 2025-09-03, 2025-09-02, and 2025-08-29), all occurring as the stock accelerated higher, with the three most recent showing 30-day gains of 27.0%, 23.2%, and 20.7% respectively. The company remains unprofitable (net income $-23.5M most quarter) despite exceptional revenue growth of +316.3% year-over-year, and trades at a 28.45 P/E multiple. The timing of this sale—after a major run-up and alongside sustained selling pressure from the same director—warrants investor attention to whether the rapid rally is sustainable given the unprofitable financial profile.

Director Kaye Edward M. MD sold 61,885 shares for $1,245,697.68 (blended avg $20.13) across 3 separate sales; held 91,585 shares post-transaction.

Kaye Edward M. MD (Director) filed 3 separate sales over five days (2025-08-29 to 2025-09-03), totaling 61,885 shares sold for $1,245,697.68 at an average price of $20.13, reducing his holdings by 40.3% from 153,470 shares to 91,585 shares. His cross-ticker track record shows a 100.00% well-timed rate on 2 prior sells, and both of his prior sales at Stoke Therapeutics (2024-05-20) were also well-timed at the 90-day mark, establishing a consistent pattern of selling ahead of subsequent declines. The stock has risen 81.7% over 90 days and is trading at $19.77, within 0.0% of its 52-week high ($19.77), while the company remains unprofitable with a net loss of $23.5M against quarterly revenue of $13.8M, creating a potential tension between recent price strength and underlying fundamentals. The timing of this large, multi-tranche liquidation, combined with his consistent prior track record of selling before subsequent weakness, warrants investor attention to the company's near-term trajectory.